Too often, recruiters are more clear on what a position will “do” rather than what it will “achieve”.Outlining tasks and responsibilities takes priority over goals and impact.But to attract top talent, you need to define and explain what success looks…
HOME > REGULATORY
REGULATORY
- Prof. Morishita Calls for New Pricing System for Innovative Drugs; Doubling Prices Yielded by Current Cost Calculation Method
February 19, 2013
- 25 Companies Receive Approval for Generic Loxonin Tape, 11 Companies for Generic Calblock
February 19, 2013
- Regulatory Reform Council’s Priority Areas Include Health, Medicine; Discussion Topics to Be Set by Feb.-End
February 18, 2013
- Notification on Clinical Trial Documents and Records Cancels Previous Rules on Paper-Based “Original Documents and Duplicate Copies”
February 18, 2013
- MHLW Panel Kicks Off Discussion on New Rules for Online Drug Sales, Won’t Cover Ethical Products
February 15, 2013
- MHLW to Set Up “Central Liaison Council” this Fiscal Year to Unify Criteria for Reviewing Medical Bills
February 15, 2013
- CSIMC OKs NHI Price Listing of 17 APIs; Peak Sales of 34 Billion Yen Projected for Eliquis
February 14, 2013
- EAD Director Kamata Encourages Generic Makers to Develop Overseas Operations
February 13, 2013
- Denotas Chewable for Hypocalcemia Associated with Administration of Denosumab Passes PAFSC 1st Committee
February 12, 2013
- Off-Label Use of Predonine for DMD Now Being Reimbursed
February 12, 2013
- Equa Gets Go-Ahead for Additional Concurrent-Use Indications of Insulin and Other Hypoglycemic Agents: PAFSC 1st Committee
February 8, 2013
- PAFSC First Committee Recommends Approval for Japan’s First FD Treatment Acofide
February 8, 2013
- Health Sciences Council to Upgrade Committee on Immunization to “Department on Preventive Vaccination and Vaccines”
February 7, 2013
- NIHS to Accelerate Medical Innovation Research
February 7, 2013
- MHLW to Launch Panel on Feb. 14 to Set New Rules for Online OTC Drug Sales
February 6, 2013
- New Council on Conflicts of Interest Holds 1st Meeting, Some Doctors Say Disclosure of Individual Payments, Recipient Names “Hasty”
February 5, 2013
- Takeda, KAKETSUKEN Apply for Funding Under Second Project to Develop and Manufacture New Flu Vaccines
February 4, 2013
- PAFSC's 2nd Committee Recommends Approval for Arzerra
February 1, 2013
- CRO Association to Compile Guidelines for Third-Party Outsourcing after GCP Revision
February 1, 2013
- Government Allocates 9 Billion Yen in FY2013 Budget to Boost Reviews and Safety Measures of Pharmaceutical Products
January 31, 2013
ページ
Pharmaceutical companies are giving high marks to Japan’s drug pricing reform for FY2024. According to a survey conducted by Jiho, 51% of all respondents expressed a positive opinion of the reform, saying that they were “somewhat satisfied” with it. The…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…